<DOC>
	<DOC>NCT00673387</DOC>
	<brief_summary>A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous (SC) injection in obese and overweight subjects.</brief_summary>
	<brief_title>Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>18 to 65 years old. Is obese (Body Mass Index [BMI]&gt;=30kg/m^2 and &lt;=35kg/m^2); or overweight (BMI&gt;=27kg/m^2 and &lt;30kg/m^2. Has stable body weight, i.e., not varying by &gt;3% within 3 months prior to study. Has not been treated over the past 3 months or is currently treated with any of the following medications: Oral contraceptives (female subjects); Hormone replacement therapy (female subjects); Metformin for the treatment of polycystic ovary syndrome (female subjects); Antihypertensive agents; Lipidlowering agents; Thyroid replacement therapy; selective serotonin reuptake inhibitors (SSRIs). Is comfortable with having repeated telephone contacts with a lifestyle counselor during the study. Is a nonsmoker (has not smoked for at least 6 months prior to the study). Has a medical history (e.g., morbid childhood obesity) and/or physical characteristics suggestive of genetic obesity or syndromatic obesity (e.g., PraderWilli syndrome, BardetBiedl syndrome). Is currently enrolled or plans to enroll in a diet, weight loss, or exercise program with the specific intent of losing weight (subjects who have been following an exercise regimen resulting in stable weight maintenance for at least 2 months prior to enrollment are eligible for study inclusion) Has been treated over the past 2 months, is currently treated, or is expected to require or undergo treatment with *antiobesity agents (prescription or overthecounter), *antipsychotic agents, *antiepileptic agents, *antidepressant agents, *drugs that directly affect gastrointestinal motility, *antidiabetic medications. Has previously received treatment with metreleptin or pramlintide in a clinical study or has received prior treatment with pramlintide (SYMLINÂ®). Has received any investigational drug within 30 days or within a period corresponding to 5 halflives of that drug, whichever is greater, prior to this study starting. Has had a major surgery or a blood transfusion, or has donated blood over the past 2 months or is planning to donate blood during the study. Has had liposuction, abdominoplasty, or similar procedure over the past year or is planning to have such a procedure during the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>overweight</keyword>
	<keyword>obesity</keyword>
	<keyword>pramlintide</keyword>
	<keyword>metreleptin</keyword>
	<keyword>Amylin</keyword>
</DOC>